FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1739-1741 October 20, 2005 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Shepherd, F. A. Related Article by Tsao, M.-S. PubMed Citation

To the Editor: Shepherd and colleagues (July 14 issue)¹ report that erlotinib prolongs survival in non–small-cell lung cancer, as compared with placebo, after the failure of first-line or second-line chemotherapy. One disturbing aspect of this trial is that some patients underwent only one prior chemotherapy regimen before randomization. These same authors previously reported that docetaxel is superior to best supportive care after first-line chemotherapy.² Subsequent studies have confirmed the efficacy of docetaxel and shown that pemetrexed achieves similar results.³ Did Shepherd and colleagues think that random assignment to placebo after the failure of first-line chemotherapy was ethically justifiable? The only . . . [Full Text of this Article]

This article has been cited by other articles:

• Kancha, R. K., von Bubnoff, N., Peschel, C., Duyster, J. (2009). Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy. Clin. Cancer Res. 15: 460-467 [Abstract] [Full Text]  
• Lara, P. N. Jr, Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., Gandara, D. R. (2008). Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non-Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. JCO 26: 463-467 [Abstract] [Full Text]  
• Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., Tsuchihashi, Z., Mauro, D. J., Rowinsky, E. K. (2006). Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. JCO 24: 4914-4921 [Abstract] [Full Text]